Amgen's second-quarter 2018 financial results and the accompanying discussion suggest several positive and stable elements that are likely to influence the stock price in the short term:

1. **Strong Financial Performance**: Amgen reported 4% top-line growth and 17% growth in non-GAAP earnings per share, driven by strong unit demand for newer products like Repatha, KYPROLIS, Prolia, and XGEVA. This indicates robust execution of their growth strategy[3].

2. **Volume-Driven Growth**: The company emphasized volume-driven growth, particularly outside the U.S., which saw 9% growth. This sustainable growth model is likely to be viewed positively by investors[3].

3. **Pipeline and Product Launches**: Amgen highlighted the successful launch of Aimovig, its first entry into neuroscience, and the progress of other products like Parsabiv and its biosimilar portfolio. These launches and pipeline advancements are expected to drive long-term growth[3].

4. **Executive Succession and Leadership**: While the departure of key executives like Sean Harper and Tony Hooper might raise some concerns, the transition plan and the introduction of new leaders like David Reese and Murdo Gordon were presented as smooth and well-planned, mitigating potential disruption[3].

5. **Guidance and Cash Flow**: The company revised its 2018 guidance upward, reflecting confidence in continued good performance. Additionally, Amgen generated significant free cash flow and committed to substantial share repurchases, which are generally positive signals for shareholders[3].

Given these factors, the overall tone of the earnings call is positive, suggesting that the stock is likely to experience a positive impact in the short term.

**Rating: 1**